Spinocerebellar ataxia (SCA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Spinocerebellar ataxia (SCA)

Spinocerebellar ataxia (SCA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Spinocerebellar ataxia (SCA) is a term referring to a group of hereditary ataxias that are characterized by degenerative changes in the part of the brain related to the movement control (cerebellum), and sometimes in the spinal cord.

Thelansis estimated that 150,000 people in the United States are affected by, or at risk for, spinocerebellar ataxia (hereditary ataxia).  Some ataxias are more common in certain ethnic groups. For example, SCA3 is more common in /the Portuguese population, SCA10 is more common in the Mexican population, and DRPLA is more common in Japan.

Competitive landscape of Spinocerebellar ataxia (SCA) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Spinocerebellar ataxia (SCA) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Spinocerebellar ataxia (SCA) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Spinocerebellar ataxia (SCA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        KPS-0373 dose        Kissei Pharmaceutical Co., Ltd.        Phase 3

2        Intravenous infusion        Sclnow Biotechnology Co., Ltd.        Phase 2

3        Intravenous Immune Globulin (IVIG)        Baxter Healthcare Corporation        Phase 1

4        troriluzole        Biohaven Pharmaceuticals, Inc.        Phase 3

5        Stemchymal        Steminent Biotherapeutics Inc.        Phase 2

6        Cabaletta        Bioblast Pharma Ltd.        Phase 2

7        varenicline        Pfizer        Phase 2

8        Deep TMS        Brainsway        Phase 2

9        human umbilical cord mesenchymal stem cells        Shenzhen Beike Bio-Technology Co., Ltd.        Phase 2

10        IB1001        IntraBio Inc        Phase 2

11        EDS-EP dose range        Erydel        Phase 3

12        Omaveloxolone Capsules        Reata Pharmaceuticals, Inc        Phase 2

13        Vatiquinone        PTC Therapeutics        Phase 3

14        CTI-1601        Larimar Therapeutics, Inc.        Phase 1

15        RT001        Retrotope, Inc.        Phase 3

16        MIN-102        Minoryx Therapeutics, S.L.        Phase 2

17        TAK-831        Takeda        Phase 2

18        interferon γ-1b        Horizon Pharma Ireland, Ltd.        Phase 3

19        alpha-tocopherolquinone (A0001)        Penwest Pharmaceuticals Co.        Phase 2

20        Lu AA24493        H. Lundbeck A/S        Phase 2

21        idebenone        Santhera Pharmaceuticals        Phase 3

22        Deferiprone oral solution 100mg/mL        ApoPharma        Phase 2

23        EGb 761 120 mg        Ipsen        Phase 2

24        (+)-Epicatechin        Cardero Therapeutics, Inc.        Phase 2

25        EPI-743        Edison Pharmaceuticals Inc        Phase 2

26        Interferon Gamma-1b        Vidara Therapeutics Research Ltd        Phase 2

27        VO659        Vico Therapeutics